Google
×
Dec 20, 2018 · Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older ...
Dec 20, 2018 · Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was ...
Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients ...
Schetelig, Johannes ; de Wreede, Liesbeth C. ; van Gelder, Michel et al. / Late treatment-related mortality versus competing causes of death after allogeneic ...
Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients ...
View statistics · In Collections · Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic ...
Sep 1, 2019 · Patients with MF have good survival when alive and in remission two years after transplantation, especially younger and female recipients.
Apr 4, 2024 · In the remission induction group, day 28 mortality after allogeneic HSCT was lower among patients who proceeded to allogeneic HSCT in complete ...
Missing: Late | Show results with:Late
People also ask
Apr 4, 2011 · Most deaths after HCT occur within the first 2 years as a result of relapse, acute or chronic graft-versus-host disease (GVHD), infection, or ...
Missing: syndromes | Show results with:syndromes
May 28, 2016 · Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT.